Epilepsy

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

Here's what is coming soon to NeurologyLive.

Investigators compared 4 treatment groups, concluding that nonstandard therapies were less effective in enacting freedom from treatment failure.

Neurology News Network for the week ending August 14, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.

Surgery for eligible patients was shown to increase rates of seizure freedom, as well as improve developmental levels, among those with TSC.

A lateralization effect was observed for patients with left temporal lobe epilepsy, as their BrainAGE values more closely resembled control group values following surgery.

Here's what is coming soon to NeurologyLive.

Jianbin Tang, data scientist and research leader from IBM Research Australia, and colleagues spoke on findings from their recent study and plans for a newly developed artificial intelligence-based model.

Neurology News Network for the week ending August 7, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 6, 2021.

There was no evidence of increased risk of suicidal ideation or attempt overall or for any individual antiseizure medication in a meta-analysis of 5 newer ASMs.

Led by a team of top talents, NYU Langone’s Comprehensive Epilepsy Center’s contributions to drug development and improving the quality of life for patients stand among the field's most important.

Preliminary results showed that a fusion of accelerometry and blood volume post modalities achieved the best AUC-ROC for 9 combined seizure types.

Aquestive does not anticipate a need for any additional studies and is preparing for the commercial launch of Libervant in the first half of 2022, if approved.

Here's what is coming soon to NeurologyLive.

Key opinion leaders discuss managing patient expectations regarding clinical trials for Dravet syndrome treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 30, 2021.

Patients with neurological sequelae from COVID-19 were significantly more likely to die before discharge (22.2%) compared with non-neuro-COVID patients (14.4%).

Many applicants referenced an early interest and exposure to neurology, often describing their first courses in neurology sparking their desire to learn more about how the brain works.

Here's what is coming soon to NeurologyLive.

A discussion of new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.

The impact of new drug approvals on the consensus guidelines for the treatment of Dravet syndrome.

Investigators observed declines in delayed verbal recall in 20% to 30% of individuals who underwent a dominant temporal lobe resection for treatment of epilepsy.

Neurology News Network for the week ending July 24, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 23, 2021.

Basis for the approval was the SENZA-PDN randomized controlled trial, which showed the system’s ability to substantially sustain pain relief and improve health-related quality of life.

Treatment retention with cenobamate ranged from 73% of patients at 1 year to 59% of patients at 6 years.

The panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.  

The panel discusses future gene therapies in development for Dravet syndrome.